2015 RPPA Global Workshop Speakers

2015 RPPA Global Workshop Keynote Speaker


Joyce A. O’Shaughnessy, MD
Celebrating Women Endowed Chair in Breast Cancer Research, Baylor University Medical Center, Dallas, Texas
Baylor Charles A. Sammons Cancer Center, Texas Oncology, Dallas Texas

"Confessions of a Breast Cancer Splitter and Therapeutic Implications"

Joyce A. O’Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O’Shaughnessy focuses on her practice and clinical research on breast cancer treatment. She is Director of Breast Cancer Research and at Baylor-Sammons Cancer Center and chair of Breast Cancer Research for The US Oncology Network.
Background / Education: Dr. O’Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995.
Memberships / Honors / Awards: Member: American Association for Cancer Research; American Society of Clinical Oncology; American College of Physicians; and Women in Cancer Research. Associate Editor: Clinical Breast Cancer Journal. Founder: The School of Breast Oncology
Research Interests: Genotype-Phenotype correlations for high risk breast cancers and immunotherapy for triple negative breast cancer.

2015 RPPA Global Workshop Speakers

 

Jennifer G. Barrett, Ph.D., DVM, Diplomate ACVS, Diplomate ACVSMR
Virginia Tech’s Marion duPont Scott Equine Medical Center, Leesburg, Virginia

“Regenerative Medicine and Tissue Engineering”

Dr. Barrett is the Theodora Ayer Randolph Professor of Equine Surgery at Virginia Tech’s Marion duPont Scott Equine Medical Center. She received her doctorate in molecular and cell biology from Yale University in 1999 and her doctor of veterinary medicine degree from Cornell University in 2002. Further training included an internship in equine medicine and surgery at Rood & Riddle Equine Hospital in Lexington, Kentucky, residency in equine surgery at the University of Illinois in Urbana, and postdoctoral orthopedic research position at the University of Wisconsin in Madison.
Dr. Barrett joined the Marion duPont Scott Equine Medical Center’s faculty in August 2007 and achieved Diplomate status through the American College of Veterinary Surgeons in 2008 and the American College of Veterinary Sports Medicine and Rehabilitation in 2013. She is a member of the American Veterinary Medical Association, the American Association of Equine Practitioners, the Veterinary Orthopedic Society, the Orthopaedic Research Society, the Tissue Engineering and Regenerative Medicine International Society, and the Phi Zeta Honor Society. She is a founding director of the North American Veterinary Regenerative Medicine Association and currently serves as Chair. Her research interests include tendon, ligament, and cartilage healing, stem cell and platelet rich plasma therapies, and tissue regeneration. She established the Regenerative Medicine Service at the EMC, which offers stem cell treatment and platelet rich plasma therapy to patients at the EMC and beyond. Her clinical interests include lameness, diagnostic imaging, and orthopedic surgery.
 

Karl-Friedrich Becker, PhD
Technische Universität München, München,Germany

"Quantitative Multi-Region Proteomics Reveals Intratumoral Heterogeneity and Identifies Distinct Sub-Proteomes in Colon Cancer”

Prof. Becker is Head of the Laboratory for Experimental Pathology at the Technical University of Munich, Germany. He identified the first gene mutations in the cell adhesion molecule E-cadherin in human tumours and demonstrated their tumour biological and clinical relevance using mutation-specific monoclonal antibodies. He is currently applying Reverse Phase Protein Arrays (RPPA) for functional protein profiling of clinical tissue samples in order to identify novel biomarkers for diagnosis and therapy of cancer patients. As partner of the European large-scale project SPIDIA and the m4 Munich Cluster of Excellence he analysed the variability of protein and phosphoprotein levels in clinical tissue specimens during the pre-analytical phase. Prof. Becker is expert and project leader of CEN/Technical Committee 140 (In-vitro Diagnostic Medical Devices) Working Group 3 and ISO/TC 212 (Clinical Laboratory Testing and In vitro Diagnostic Test Systems) Working Group 4.
 

Jonathan Bones, PhD
National Institute for Bioprocessing Research and Training, Dublin, Ireland

“Bolstering the Glycoanalytical Tool Box, Mining Deeper in Search of Disease Specific Alterations in Glycosylation”

Jonathan is the Principal Investigator of the NIBRT Characterization and Comparability Laboratory. Jonathan received a PhD in Analytical Chemistry in 2007. Following this he undertook postdoctoral research with Prof. Pauline Rudd at NIBRT. In 2010 Jonathan moved to Northeastern University in Boston, working with Prof. Barry L. Karger at the Barnett Institute of Chemical and Biological Analysis. Jonathan returned to NIBRT in 2012 following receipt of funding from Science Foundation Ireland to form his own independent research group. His research is focused on the development and application of advanced LC-MS and CE-MS solutions to solve challenges associated with the characterization and comparability assessment of therapeutic proteins and manufacturing processes as well as understanding complex biological systems.

Adam Byron, PhD
Edinburgh Cancer Research UK Centre, Edinburgh, United Kingdom

“Building RPPA Data into Cancer Signaling Networks”

Dr. Adam Byron is a Research Fellow at the Edinburgh Cancer Research UK Centre, University of Edinburgh, in the laboratory of Professor Margaret Frame. His research develops and implements proteomic approaches to investigate mechanisms of cancer cell adhesion (see http://adambyron.com).
He received his PhD in Biochemistry from the University of Manchester, where he studied cell adhesion in the research group of Professor Martin Humphries, and where he stayed to undertake postdoctoral work. Here, he developed methodologies for the isolation and proteomic analysis of integrin adhesion complexes, which led to the description of the first experimentally defined integrin proteomes and insight into the complexity of the molecular machinery of cell adhesion. Prior to his PhD, he studied Biochemistry at the University of Warwick, where he was awarded both Biochemistry Prizes and was selected to spend an Intercalated Year of his degree working at AstraZeneca.
He is a Member of the Royal Society of Biology, the British Society for Proteome Research, the British Society for Matrix Biology, the British Society for Cell Biology and an Early Career Member of the Biochemical Society. He received the 2009 Early Career Investigator Award from the British Society for Proteome Research and the 2010 Young Investigator Award from the British Society for Matrix Biology. In 2013, he was awarded Chartered Biologist status by the Royal Society of Biology and Associate Fellowship of the Higher Education Academy.
 

Leisha A. Emens, MD, PhD
Johns Hopkins University School of Medicine, Baltimore, Maryland

"Immunotherapy: The Next Revolution of Cancer Treatment"

Leisha A. Emens, M.D., Ph.D., is an Associate Professor of Oncology at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine. She is a medical oncologist who specializes in breast cancer care, and is a member of both the cancer immunology and the breast/ovarian cancer research programs. Her research is focused on developing innovative immune-based therapies that combine cancer vaccines, immune checkpoint inhibitors, and other immune modulators with standard treatments for breast cancer and ovarian cancer. She developed a cytokine-secreting breast cancer vaccine for testing in clinical trials. Using a preclinical murine breast cancer model of antigen-specific tolerance, she develops rational combinatorial immunotherapy strategies to overcome immune tolerance and translates the most promising immunotherapy regimens to the clinic. Dr. Emens is on the editorial boards of Cancer Research, and the Journal for the Immunotherapy of Cancer. She is chair of the Stakeholder’s Council of the Society for the Immunotherapy of Cancer, and is a member of the FDA Advisory Committee on Cellular, Tissue, and Gene Therapies. She is an active member of ASCO, AACR, and SITC.

Leanne de Koning, PhD
Institut Curie, Paris, France

“Reverse Phase Protein Arrays as a tool to identify new biomarkers and potential therapeutic targets for invasive lobular breast cancer”

Dr. Leanne de Koning obtained her Master of Biomedical Sciences at the University of Amsterdam (The Netherlands). She moved to Institut Curie in Paris (France) for her PhD on chromatin dynamics in breast cancer in the laboratory of Dr. G. Almouzni. She joined the Translational Research Department of Institut Curie in 2009 to set up, develop and lead a Reverse Phase Protein Array platform. The aim of this platform is to investigate cell signaling pathway activity and to identify candidate therapeutic targets and predictive biomarkers. Dr. De Koning is involved in projects ranging from fundamental research to clinical trials, and works in close collaborations with scientists, physicians and statisticians. She is also actively involved in international collaborations and networks. Proving new biological insight to improve the treatment and the outcome of cancer patients is her main motivation.
 

Victoria de Lange, PhD
ETH Zurich, Zurich, Switzerland

“The 3D Microarray: Developments, Applications, and Future Directions”

Dr. Victoria de Lange completed her PhD in the Laboratory of Biosensors and Bioelectronics (LBB) at ETH Zurich in 2015 under the supervision of Prof. Dr. Janos Vörös. The focus of her research at LBB was centred on innovative 3D microarray formats for low-cost, multiplexed protein detection in clinical sample volumes. As part of her thesis research she developed the FoRe microarray, for which she was awarded several poster prizes at international conferences. Victoria received her Bachelor of Electrical Engineering (with honours, specialising in Electronics) from the University of Victoria, Canada in 2008. Upon completing her studies she was awarded the Association of Professional Engineers and Geoscientists Achievement Award in Electrical Engineering. Victoria received the NSERC Alexander Graham Bell Graduate Award to complete her masters in biomedical engineering at ETH Zurich. The focus of her master’s thesis was hydrogel-based protein microarrays. Her research interests are protein microarrays and developing simplified and multiplexed protein sensors.

Virginia Espina, PhD, MT (ASCP)
George Mason University, Manassas, Virginia

“A New Frontier for Molecular Profiling of Bone”

Virginia (Ginny) Espina, PhD, MT(ASCP) is a Research Associate Professor and Director of the CAP accredited clinical proteomics laboratory at George Mason University (Manassas, Virginia, USA) in the Center for Applied Proteomics and Molecular Medicine. Dr. Espina’s career began as a Medical Technologist with extensive experience in clinical chemistry and Blood Banking. She received her Master's in Biotechnology from Johns Hopkins University and a PhD in Biosciences from George Mason University. Dr. Espina is the former Manager of the Laser Capture Microdissection Core facility at the NIH/National Cancer Institute. At George Mason University, Dr. Espina implemented and maintains the CAP-accredited clinical proteomics lab for clinical trial research.
The studies performed by Dr. Espina have involved a wide spectrum of proteomic approaches, including classical western blotting, laser capture microdissection and reverse phase protein microarrays, that yielded elucidation of phosphorylation specific kinase events in the tumor-host microenvironment of multiple myeloma, breast, lung, and ovarian cancer. Ms. Espina’s responsibilities include lab management for the CAP/CLIA accredited clinical trial laboratory, co-PI on the PINC trial, a breast DCIS chemoprevention clinical trial, as well as translational research involving nanoparticle applications for harvesting biomarkers, identification of breast cancer progenitor cells in pre-invasive lesions, and elucidation of cell signaling cascades in cancer and infectious disease. Ms. Espina is the lead scientist developing phosphoprotein preservatives as an alternative to formalin fixation.

She is on the editorial board of Molecular and Cellular Proteomic and serves as a peer reviewer for several journals. Dr. Espina is an author of more than 90 peer-reviewed publications and editor of Molecular Profiling in Methods in Molecular Biology. She holds 4 issued patents related to new technologies and therapeutic applications.

Philip L. Felgner, PhD
University of California, Irvine, California
*Grace Bio-Labs Sponsored Speaker*

“Understanding the Antibody Response to Infectious Diseases with Whole Proteome Microarrays”

Under his direction the Protein Microarray Laboratory at UCI has generated 60,000 individual plasmids derived from dozens of infectious viruses, bacteria and parasites. Proteins expressed from these plasmids can be printed on microarrays and probed with sera from disease cases and healthy controls to identify antibody responses associated with infection, and to discover vaccine and serodiagnostic antigens. For 10 years the lab was the Trans-RCE Core for the 10 Regional Centers of Excellence for Biodefense which greatly expanded the network of clinical investigators that the lab interacts, and increased the number of infectious disease targets investigated. In 2012 Dr. Felgner was awarded the Immunology Supplement for the International Centers of Excellence for Malaria Research (ICEMR) and he directs the Protein Microarray Core probing 1,500 specimens per year from 30 clinical sites in 10 malaria endemic regions around the world. Since moving from industry to UC Irvine in 2002 Dr. Felgner published 101 papers in peer reviewed journals. His portfolio of 178 publications on Medline has been cited more than 27,000 times. He is an inventor who discovered the ‘Lipfection’ reagents so widely used in molecular and cellular biology. He also discovered ‘DNA vaccines’ leading to the founding of Vical Inc., a publically traded biotechnology company. At UCI he developed the whole proteome microarray approach which was licensed by a small business he founded in Irvine, Antigen Discovery Inc. (ADI).
 

Marcel Geertz, PhD
Bayer Technology Services, Leverkusen, Germany
*Arrayjet Sponsored Speaker*

"RPPA Mediated Characterization of Cell-Based Assays to Support Mechanism-of-Action Studies”.

Dr. Marcel Geertz is Technology Manager Proteomics at Bayer Technology Services GmbH (BTS). Dr. Geertz studied biology and specialized in the development and application of omics technologies for the elucidation of gene and protein regulatory networks. He joined BTS in 2014 and is currently leading R&D projects, involving the development and application of reverse phase protein array technology. Previously, he worked at Philip Morris Products S.A., where he was leading the Antibody-based proteomics laboratory.
 

Taran Gujral, PhD
Harvard Medical School, Cambridge, Massachusetts
*Innopsys Sponsored Speaker*

“Wnt-Frizzled Signaling in Epithelial-Mesenchymal Transition and Cancer”

Taran Gujral is a Research Fellow in Systems Biology at Harvard Medical School. His research focuses on understanding mammalian signaling pathways that drive cancer metastasis and resistance to therapy. Previously, he worked with Dr. Gavin MacBeath in the Department of Chemistry and Chemical Biology at Harvard University, where he developed experimental methods for multiplex protein measurements. He received a Bachelor of Science (Honors) in Life Sciences and Mathematics, a M.Sc. in Pathology & Molecular Medicine and a Ph.D. in Trans-disciplinary Cancer Research, all from Queen’s University, Canada.

Harvey J. Kliman, MD, PhD
Yale University School of Medicine, New Haven, Connecticut

“The Human Placenta Structure and Function in Health and Disease (including Autism)”

Harvey J. Kliman is an MD, PhD graduate in Medicine and Cellular Biochemistry from the University of Chicago. He is currently a Research Scientist in the Department of Obstetrics and Gynecology, Yale University School of Medicine, and the Director of the Reproductive and Placental Research Unit with a special interest in infertility and pregnancy complications. He has over thirty-five years of anatomic pathology training with particular emphasis in electron microscopy, immunohistochemistry, endometrial and placental physiology and cellular biology. He has over ten patents, including the patent for the Endometrial Function Test® (EFT®)—“The soil test for the endometrium®” and “Method and system for determining placental volume.” His contributions in the field of placental research include the development of the “Kliman” method of trophoblast purification, research into the mechanisms of trophoblast differentiation and invasion, the role and genesis of syncytial knots, the discovery of fetal fibronectin, and more recently, the clinical utility of abnormalities in placental villous growth patterns, especially trophoblast invaginations and inclusions, to diagnose genetic abnormalities in pregnancy, including autism. He developed the PlacentASD® Test, which is the only test that can determine the risk of Autism Spectrum Disorder (ASD) at birth.
In addition to his research and teaching activities at Yale, he also consults with doctors, patients and lawyers to evaluate complicated cases of unexplained infertility, pregnancy loss, and poor pregnancy outcomes.
An extensive website with articles, abstracts, lab activities, and past and present students and staff can be found at: klimanlabs.yale.edu

Michael Lee, PhD
UMass Medical School, Worcester, Massachusetts

“Environmental and Context Dependent Regulation of Chemosensitivity, A Systems Biology Perspective”

Michael Lee received his BS degree in Cell Biology from the University of Washington in 2002, where he studied the function and regulation of non-receptor tyrosine kinases in the immune system, first in the laboratory of Steven D. Levin, and subsequently with Michael J. Bevan. Working in Henrik G. Dohlman's lab, Mike went on to receive his PhD in Pharmacology from the University of North Carolina at Chapel Hill in 2008 for work studying the enzymology, sub cellular localization, and mechanisms of activation of heterotrimeric G proteins. For postdoctoral training, Mike moved to the Koch Institute for Integrative Cancer Research at MIT, where he worked with Michael B. Yaffe. His work at MIT focused on crosstalk between growth factor and DNA damage signaling networks and how these features altered combination drug therapies. Mike joined the Program in Systems Biology in late 2013. His lab studies complex behaviors of signaling networks that control cell death, how network state and network architecture are perturbed in various forms of cancer, and how these perturbations contribute to treatment responses. They aim to identify guiding principles for designing rational combination drug therapies for breast and other types of cancer.

Robert Martone
St. Jude Children's Research Hospital, Memphis, Tennessee

“Childhood Cancer: Future Challenges and New Directions”

Robert Martone conducts biomarker research and development with a focus on neuro-oncology in the Department of Pathology at St. Jude Children's Research Hospital. He was previously Neuroscience Therapeutic Area Lead for the Covance Biomarker Center of Excellence and Senior Principal Scientist at Wyeth Neuroscience. He has extensive experience in the pharmaceutical industry having led neuroscience drug discovery and technology teams through all phases of discovery from target identification through clinical trials with expertise in both small molecule and protein therapeutics. He also has several years of academic research experience in molecular neurobiology, with a focus on the molecular genetics and pathophysiology of familial neuropathies.

Peter Nilsson, PhD
KTH – Royal Institute of Technology, Stockholm, Sweden

“Human Protein Atlas Enabled Neuroproteomic Profiling of Body Fluids”

Peter Nilsson is Professor in Proteomics at SciLifeLab Stockholm, KTH – Royal Institute of Technology. He has since 2002 been heading the Protein Microarray group within the Human Protein Atlas project. He is the executive director of the Affinity Proteomics national platform at SciLifeLab and the site director of the Human Protein Atlas at SciLifeLab Stockholm. He is also the vice dean of the School of Biotechnology at KTH.
The main research focus is within development and utilization of various protein microarray formats for biomarker discovery through peptide, antigen and antibody based proteomic profiling of body fluids. See http://publicationslist.org/nipe for a complete list of publications.

Emanuel Petricoin III, PhD
George Mason University, Manassas, Virginia

Dr. Emanuel F Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. Prior to this position, he served as Co-Director of the FDA-NCI Clinical Proteomics Program and a Senior Investigator within the Center for Biologics Evaluation and Research at the FDA from 1993-2005. Dr. Petricoin received his PhD in Microbiology from the University of Maryland in 1990. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, and biomarker discovery and measurement for direct clinical applications at the bedside. He is a co-founder of 4 life science companies, Theranostics Health, Inc, Ceres Nanosciences Inc., C-4 Diagnostics, Inc. and Perthera, Inc. He is a co-inventor on 40 filed and published patents, and has authored over 350 peer-reviewed publications and invited reviews. He has authored over 40 book chapters, is on the editorial board of Proteomics, Biomedical Microdevices, Proteomics- Clinical Applications, Proteomics- Protocols, Molecular Carcinogenesis, Journal of Personalized Medicine and is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO) as well as the US HUPO and served on the Executive Committee and Treasurer for HUPO from 2002-2004. He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is s Kentucky Colonel. He is the faculty representative to the George Mason University Research Foundation and represents GMU on the Board of Directors for the Virginia Health Research Biosciences Corporation.

Giorgio Stassi, MD
University of Palermo, Palermo, Italy

“Cancer Stem Cells: Finally the Answer to Durable Cancer Treatment?”

Giorgio Stassi started his research activity in 1989 at the Institute of Clinical Medicine of the University of Palermo. His research activity focused on the molecular mechanisms which regulate programmed cell death, a part of biomedical research which in those years received particular interest in the scientific-academic world. His contribution clarified the role of apoptosis in Hashimoto's thyroiditis and other endocrine pathologies.
In 1997 he started work at the Rangos Research Center (PA) USA, under the supervision of Prof. Trucco and worked on the pathogenesis of Diabetes Mellitus.
He returned to Italy in 2000 at the University of Palermo where he continued the study of cellular death in the pathogenesis of autoimmune diseases. During the first years at the University of Palermo, Stassi and his team published a series of articles in well- known journals such as Science, Nature, Journal of Experimental Medicine, and Nature immunology which, are essential for the understanding of the pathogenic mechanisms of autoimmune diseases.
In 2002 he took position as Manager of the Cellular and Molecular Pathophysiology Laboratory at the Department of Surgical and Oncological Sciences of the University of Palermo. Through a tight contact with the clinic, Stassi brought mechanisms to light which regulate the survival and resistance to conventional therapies in epithelial tumor cells. These results contributed in a fundamental manner to oncology research consenting Stassi to formulate a patent which contributed to the development of new cancer neoadjuvant therapies for the treatment of colon, breast and thyroid tumors. In the last 10 years his scientific interest has been focused on the study of the role that cancer stem cells have in the onset and the progression in different tumors of epithelial origin such as colon, breast and thyroid tumors.

Marie-Claire Wagle, PhD
Genentech, San Francisco, California

"A role for FOXO-1 in BCR-ABL1 Kinase-Independent Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia”

Dr. Wagle is currently a senior scientific researcher in the Oncology Biomarker Development (OBD) group at Genentech. She is involved in the discovery and development of predictive and pharmacodynamic biomarkers that are used in early stage clinical trials and has extensive experience of using Reverse Phase Protein Arrays for exploratory, preclinical and clinical applications. One of her main interests is in the development of PD assays that are capable of deriving phospho-proteomic data from very sparse clinical samples. To this end, she has worked with Theranostics Health to develop and optimize RPPA assays for use with microdissected core-needle biopsies. Prior to joining Genentech, Dr. Wagle worked at Nuvelo to support the development of cancer biologics and to determine their mechanisms of action. She obtained her doctorate in Cell and Molecular biology from the University of East Anglia in England in 2002 and shortly thereafter pursued her postdoctoral training in TGF-beta signaling at UCSF with Professor Rik Derynck.

David Weinberg, PhD
Eunice Kennedy Shriver National Institute on Child Health and Human Development (NICHD), Bethesda, Maryland

“Future Directions of Placental Research at the NIH: The Human Placenta Project”

David Weinberg received his Ph.D. in molecular biology from Johns Hopkins University in 1983 where he studied the biology of the human Adenovirus Type 2 Early Region 4. In 1990 Dr. Weinberg joined Merck Research Laboratories where he focused on early phase drug discovery and translational research, including target identification and validation, tool generation, assay development and project advancement with particular expertise in CNS GPCR targets aimed at treating metabolic disorders. In 2009 he moved to NIH as a Scientific Review Officer, first at the Center for Scientific Review and subsequently at the Eunice Kennedy ShriverNational Institute of Child Health and Human Development (NICHD), where much of his efforts were directed at review of applications related to female reproduction and contraception. In 2014, Dr. Weinberg moved from scientific review to become the project lead for NICHD's newly launched Human Placenta Project, whose goal is to accelerate the capability for safe, real-time assessment of placental development and function. In this role he is using his experience in translational science, industry and government to move the project forward.


Gordon Whiteley, PhD
SAIC, Frederick Maryland

“Caught in a bind: finding the right antibodies”

Gordon Whiteley is a graduate of the University of Toronto with a Ph.D. in microbiology and minors in biochemistry and immunology. Following graduation, he became the clinical microbiologist for MDS Health Group Limited, the largest clinical diagnostic laboratory in Canada with responsibilities for the routine microbiology labs in locations throughout Canada and the United States. Gordon was next recruited to Syva Company in Palo Alto where he was the manager of the team that developed and commercialized non-culture methods for the detection of Chlamydia, Herpes and other STD’s as well as immunological culture confirmation reagents for the same group of diseases. He then went to Serono Diagnostics in Boston as the Director of Research and Development responsible for the development of magnetic bead based ELISA based assays for infectious diseases and the adaptation to and co-development of automated instrumentation to run the tests. He moved on to PB Diagnostics / Dade-Behring where he was part of the original development team and then became the Vice President of Research and Development responsible for the development and commercialization of tests for a wide variety of analytes including steroids and hormones, tumor markers, therapeutic drugs, thyroid tests, infectious diseases and fertility markers. Gordon moved to SAIC-Frederick in 2002 to become Director of the Clinical Proteomics Reference Lab and is now the Director of the Antibody Characterization Lab for the Frederick National Lab for Cancer Research which is part of the Clinical Proteomics Technologies for Cancer Initiative of the National Cancer Institute. Gordon has more than 25 years in the diagnostic industry that includes all phases of diagnostic testing in a clinical setting. He has commercialized over 75 products through both the FDA and international regulatory agencies.

Tesshi Yamada, MD, PhD.
National Cancer Center Research Institute, Tokyo, Japan

“Global Pathway Profiling of a Novel TNIK Inhibitor using RPPA”

I founded the Cancer Proteomics Project at the National Cancer Center (Tokyo, Japan) in 2001 and has been serving as a leader of clinical proteomics in Japan. An integrated quantitative MS platform 2DICL DICAL (2Dimensional Image Converted Analysis of LCMS), high-density fluorescent Reverse-Phase Protein Array (RPPA), and other original antibody-based and MS-based clinical proteomics methods have been developed in the project. Using these technologies I discovered many biomarkers and therapeutic targets for a large variety of cancers, and those were published in many prestigious journals such as MCP, Cancer Research, Gastroenterology, and Journal of Clinical Oncology. I organized the 8th Japan Human Proteome Organization Conference (JHUPO) and 6th Annual Meeting of Japan Society for Clinical Proteomics (JSCP) Joint Conference in 2010. The joint conference brought together more than 400 participants from Japan and abroad (Korea, Taiwan, Sweden, Canada, and U.S) and was concluded with great success. RPPA technology is highly advantageous for clinical proteomics in view of its high sensitivity as well as accurate quantification of signaling molecules. RPPA has now begun to be incorporated into various clinical trials employing molecular-targeted therapeutics. The RPPA Global Workshop is aimed at accelerating the exchange of rapidly expanding knowledge of this fascinating technology among academic laboratories and industries worldwide. I hope your participation and the great success of RPPA 2015.